Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care

Posted: 2021-09-13 19:00:00
Objectives: The hypothesis of this study is that tocilizumab should affect common signs of infection due to its immunosuppressive properties. Primary aim of the study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19, led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. Secondary aim was investigating differences in laboratory parameters between groups. Methods: Single-centre retrospective study, enrolling COVID-19 patients who developed a microbiologically confirmed infectious complication [ventilator associated pneumonia or bloodstream infection] after intensive care unit [ICU] admission and either treated with tocilizumab or not [controls]. Results: A total of 58 patients were included, 25 treated with tocilizumab and 33 controls. Median time from tocilizumab administration to infection onset was 10 days [range 2-26]. Patients were 78% male, with median age 65 years [range 45-79]. At first clinical presentation of the infectious event, the frequency of hypotension [11/25, 44% vs. 11/33, 33%], fever [8/25, 32% vs. 10/33, 30%] or hypothermia [0/25,0%, vs. 2/33, 6%], and oxygen desaturation [6/25, 28% vs 4/33, 12%], as well as the frequency of SOFA score increase of ≥ 2 points [4/25, 16%,vs. 4/33, 12%] was similar in tocilizumab treated patients and controls [p>0.1 for all comparisons]. Among laboratory parameters, C-Reactive Protein elevation was reduced in tocilizumab treated patients compared to controls [8/25, 32% vs. 22/33, 67%, p=0.009]. Conclusion: The clinical features of infectious complications in critically ill patients with COVID-19 admitted to ICU were not affected by tocilizumab. Keywords: BSI; C-reactive protein; COVID-19; Candidemia; ICU; Procalcitonin; Tocilizumab; VAP.

参考サイト PubMed: covid-19

Powered by Stromvergleich


7月 06, 2020 バイオアソシエイツ


MMRワクチン(はしか、おたふく風邪、風疹)の投与は、 COVID-19 感染に関連する敗血症性炎症を抑制する予防策として役立つ可能性があると、2020年6月19日にアメリカ微生物学会のmBioジャーナルで発表された。この論文は、「COVID-19感染に関連する敗血症性炎症を抑制する予防策として、無関係の生弱毒化ワクチンが役立つだろうか?(Could an Unrelated Live Attenuated Vaccine Serve As a Preventive Measure to Dampen…